Healthcare / BiotechnologyNasdaqCM
$1.39
-0.02 (-1.42%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-23.6M · quality 50.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
18/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$37M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-195.3%
↓Gross Margin
N/A
•Debt/Equity
0.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2017–2025 · 8 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-47248.0%
FCF / Net income
0.51x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $50000.0 · net income $-45.9M · FCF $-23.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | $50000.00 | $50000.00 | $14000.00 | $155000.00 | $374000.00 | $181000.00 | $11000.00 | — | $0.00 | $0.00 |
| Net Income | $-45.9M | $-45.9M | $-42.1M | $-30.0M | $-27.3M | $-30.3M | $-12.1M | $-7.7M | $-12.4M | $-831486.00 |
| EBITDA | $-30.8M | $-30.8M | $-42.6M | $-29.7M | $-26.0M | — | — | — | — | — |
| EPS | — | — | -2.11 | -1.67 | -1.52 | -1.88 | — | — | — | — |
| Operating Margin | -61738.0% | -61738.0% | -304535.7% | -19187.7% | -6938.8% | -16106.6% | -111163.6% | — | — | — |
| Net Margin | -91866.0% | -91866.0% | -300585.7% | -19360.0% | -7299.2% | -16762.4% | -109990.9% | — | — | — |
| Balance Sheet | ||||||||||
| Debt/Equity | 0.04 | 0.04 | 0.01 | 0.27 | 0.25 | 0.19 | — | — | — | — |
| Current Ratio | 4.24 | 4.24 | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||
| Free Cash Flow | $-23.6M | $-23.6M | $-33.4M | $-12.0M | $-22.7M | — | — | — | — | — |
| Returns | ||||||||||
| ROE | -195.3% | -195.3% | -131.1% | -78.7% | -45.4% | -37.8% | -31.2% | -32.5% | -75.2% | -4.6% |
| Valuation | ||||||||||
| P/B | 1.57 | 1.57 | 3.29 | 6.08 | 2.09 | — | — | — | — | — |
| Growth & Yield | ||||||||||
| Revenue Growth | 257.1% | 257.1% | -91.0% | -58.6% | — | 1545.5% | — | — | — | — |
| EPS Growth | — | — | -26.3% | -9.9% | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-81.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.11 → n/d
Residual
-81.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.